Table 2. HIF-1α and associations with clinico-pathologic tumor and molecular characteristics.
| Variable | HIF-1α Weak (SI = 0–2) (n; %) n = 96 | HIF-1α Strong (SI = 3–9) (n; %) n = 165 | OR 95% CI | P-value |
|---|---|---|---|---|
| Age in years | ||||
| <50 | 57 (41) | 81 (59) | 1 | |
| ≥50 | 33 (33) | 67 (67) | 1.4 (0.8–2.4) | NS |
| Histologic type | ||||
| Ductal carcinoma (NST) | 80 (35) | 149 (65) | 1 | |
| Others | 16 (50) | 16 (50) | 0.5 (0.3–1.1) | NS |
| Histologic grade | ||||
| Grade 1 | 16 (57) | 12 (43) | 1 | |
| Grade 2 | 32 (39) | 51 (61) | 2.1 (0.9–5.1) | 0.086 |
| Grade 3 | 48 (32) | 102 (68) | 2.8 (1.2–6.5) | 0.011 |
| Nuclear grade | ||||
| Grade 1 | 24 (57) | 18 (43) | 1 | |
| Grade 2 | 38 (35) | 72 (65) | 2.5 (1.2–5.2) | 0.011 |
| Grade 3 | 34 (31) | 75 (69) | 3.0 (1.4–6.1) | 0.003 |
| Mitotic count | ||||
| 0–6 | 22 (46) | 26 (54) | 1 | |
| 7–13 | 8 (18) | 37 (82) | 3.9 (1.5–10.1) | 0.004 |
| >13 | 66 (39) | 102 (61) | 1.3 (0.7–2.5) | NS |
| Ki-67 proliferative rate | ||||
| Low (<20.0%) | 52 (45) | 63 (55) | 1 | |
| High (≥20.0%) | 41 (29) | 101 (71) | 2.0 (1.2–3.4) | 0.007 |
| p53 expression | ||||
| Low, SI = 0–4 | 74 (41) | 105 (59) | 1 | |
| High, SI = 6–9 | 21 (27) | 58 (73) | 1.9 (1.1–3.5) | 0.023 |
| ER expression | ||||
| Positive (≥10%) | 33 (34) | 65 (66) | 1 | |
| Negative (<10%) | 61 (38) | 99 (62) | 0.8 (0.5–1.4) | NS |
| PR expression | ||||
| Positive (≥10%) | 19 (28) | 49 (72) | 1 | |
| Negative (<10%) | 73 (39) | 115 (61) | 0.6 (0.3–1.1) | NS |
| HER2 expression | ||||
| Negative, score 0–2+ | 74 (36) | 133 (64) | 1 | |
| Positive, score 3+ | 20 (40) | 30 (60) | 0.8 (0.4–1.6) | NS |
| Axl expression | ||||
| Weak, SI = 0–2 | 29 (53) | 26 (47) | 1 | |
| Strong, SI = 3–9 | 62 (33) | 126 (67) | 2.3 (1.2–4.2) | 0.008 |
SI, staining index; NST, no special type; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.